DopAmide, or L-DopAmide, is a synthetic levodopa (L-DOPA) analogue and levodopa and dopamine prodrug which is of potential interest in the treatment of Parkinson's disease.[1][2][3] It is a water-soluble prodrug of levodopa that is slowly cleaved into levodopa by aminopeptidase enzymes.[1][2][3] The drug is the analogue of levodopa wherein its carboxyl group has been replaced with an amide.[2][3] It might allow for reduced fluctuations in dopamine levels compared to levodopa therapy.[2]
Clinical data | |
---|---|
Other names | L-DopAmide; 3-Hydroxytyrosinamide |
Drug class | Monoamine precursor; Dopamine receptor agonist |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C9H12N2O3 |
Molar mass | 196.206 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ a b Kang T, Miao Z, Liu S, Ke B (2021). "Prodrug Strategies in the CNS Drugs: Small Modification Makes Big Improvements". Curr Top Med Chem. 21 (24): 2157–2169. doi:10.2174/1568026621666210727163827. PMID 34315372.
- ^ a b c d Urso D, Chaudhuri KR, Qamar MA, Jenner P (November 2020). "Improving the Delivery of Levodopa in Parkinson's Disease: A Review of Approved and Emerging Therapies". CNS Drugs. 34 (11): 1149–1163. doi:10.1007/s40263-020-00769-7. PMID 33146817.
- ^ a b c Atlas D (June 2016). "DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons". CNS Neurosci Ther. 22 (6): 461–467. doi:10.1111/cns.12518. PMID 26861609.